---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000002"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:40:11.100494+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "low"
source: SEC EDGAR
---

# Immunovant provides Phase 3 update for batoclimab in myasthenia gravis

## Summary
- Corporate webcast held Jan 5, 2022; presentation focuses on Phase 3 development of batoclimab.
- Batoclimab is the company's lead anti-FcRn antibody candidate for myasthenia gravis.
- No specific clinical data or milestones were disclosed in the filing or attached presentation.
- Update may include trial design, enrollment status, or regulatory timeline; details not provided.

## SEC filing metadata
- accession: 0001764013-22-000002
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000002/0001764013-22-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000002/imvt-20220105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000002
- JSON: https://secwatch.observer/filing/0001764013-22-000002.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.